Annual Drug Patent Expirations for MEGACE+ES
Megace Es is a drug marketed by Endo Pharms Inc and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.
Drug patent litigation for MEGACE ES.
This drug has thirty-three patent family members in nineteen countries.
The generic ingredient in MEGACE ES is megestrol acetate. Additional details are available on the megestrol acetate profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
